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ABSTRACT:  Significant advances in hematopoietic stem cell transplantation (HSCT) has
resulted in a large cohort of patients surviving more than 20 years after transplantation for
hematological and malignant disorders. The increased number of long-term survivors has provided
an unique opportunity to study the late effects of the HSCT. This review describes the late
complications of HSCT related to the conditioning regimen, recurrence of primary malignancy and
transplant-related toxicity with an emphasis on diagnosis and treatment of chronic graft-versus-
host disease.
UNITERMS:  Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation. Graft
VS Host Disease.  Toxicity. Follow-Up Studies.
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Hematopoietic stem cell transplantation (HSCT)
has evolved into a modern therapeutic modality for a
variety of life-threatening hematologic, neoplastic,
immunologic and genetic diseases. Around the world
thousands of patients are surviving more than five years
after HSCT resulting in an increase interest in long-
term outcome and late transplant complications(1).
Late complications after HSCT include
transplant-related toxicity (i.e., chronic graft-versus
host disease occuring after allogeneic HSCT and
immunodeficiency); conditioning-related toxicity
(several organ toxicity and secondary malignancy) and
relapse of primary malignancy (Table I). The time
to develop these late complications in relation to the
transplant is shown in Figure 1 and the interactions of
these complications and their therapies is displayed in
Figure 2.
1. CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD)
Chronic graft-versus-host disease (cGVHD) is
an immunologic disorder initiated by immunocompetent
donor lymphocytes recognizing and reacting against
recipient (patient=host) antigens on a variety of tissues.
Chronic GVHD is a clinical-pathological entity with
features similar to autoimmune diseases such as
scleroderma, systemic lupus erythematosus, Sjogren’s
syndrome, rheumatoid arthritis and primary biliary
cirrhosis(2,3). During the early phase of the disease,
dermal and gastrointestinal manifestations are similar
to acute GVHD. Chronic GVHD is usually diagnosed
after 3 months of HSCT, and may involve several
organs. HLA-disparity, history for acute GVHD and
older patient age are factors associated with an
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Figure 1: Chronology of late complications after hematopoietic stem cell transplantation (HSCT). mo - months. γr year
Table I - Classification of late complications of
hematopoietic stem cell transplantation (HSCT)
Transplant-related:
  Chronic graft-versus-host disease (GVHD)
− Limited
− Extensive
  Immunodeficiency and infections
Regimen-related
− Cataracts
− Neurological complications
− Endocrine and growth abnormalities
− Gonadal dysfunction
− Gynecologic and obstetric complications
− Secondary malignancies
Others
− Avascular necrosis
− Osteoporosis/osteopenia
Relapse of malignancy
increased risk for the development of cGVHD(4-6).
Extensive cGVHD was observed in 33% of HLA-
identical sibling transplantation and in 80% of unrelated
or mismatched transplant recipients(6). Platelets below
100,000/cu.mm at diagnosis of cGVHD and progressive
onset (acute GVHD evolving to cGVHD) are factors
associated with poor survival.
Shullman and Sullivan defined the clinical-patho-
logical classification of cGVHD in two forms: limited
and extensive (Table II)(2,3). Limited disease was
defined as signs and symptoms involving one organ
with biopsy revealing characteristic histopathological
findings. Extensive disease was defined as signs and
symptoms involving more than one organ with at least
one biopsy showing characteristics of either general-
ized or localized skin involvement and/or 1) hepatic
dysfunction due to cGVHD plus liver histology with
chronic aggressive hepatitis, 2) eye involvement with
decreased Schirmer’s test (less than 5 mm), or 3) in-
volvement of minor salivary glands with Sjogren’s syn-
drome and 4) involvement of any other target organ(3,7).
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In addition to clinical performance score (Table
III), weight loss (>15%) is also a feature of clinical
extensive cGVHD even when only one organ is
affected by the disease. Early detection and aggressive
treatment of  cGHVD (see below) appears to have
decreased the incidence of contractures and other
manifestation of cGVHD after bone marrow
transplantation. The nature and course of cGVHD
after periphearal blood stem cell transplant is still early
to assess.
As shown in Table IV, cGVHD is classified in
three subgroups according to the type of onset:
Progressive onset of cGVHD emerges as a direct
continuation of acute GVHD and it is associated with
high mortality rate; quiescent onset of cGVHD
occurs after complete resolution of the manifestation
of acute GVHD and it is associated with an
intermediate prognosis; de novo onset of cGVHD
occurs in patients without a prior history of acute
GVHD and it is associated with a better prognosis
compared to progressive onset and de novo onset of
extensive cGVHD(3,4,7,8 ).
Manifestations of cGVHD varies according to
the organ involved by the disease (Figure 3). Signs
and symptoms of cGVHD are described in details
below.
1.1. Organ involvement in chronic GVHD
1.1.1. Skin
Skin manifestations include erythema, dryness,
pruritis, pigmentary changes, mottling, plaques,
exfoliation (ichtiosis), maculo-papular or urticarial rash.
In some patients clinical features may resemble
morphea and occasional nodules can be seen. In
others, scleroderma (indurated or hide-bound) may lead
to decreased range of motion and joint contractures.
Skin biopsy shows characteristic pathological
findings(9).
1.1.2. Nails/Hair
Patients may have ridging, onichodistrophy and
onycholysis in nails. Partial or scarring alopecia and
premature graying may be observed on scalp hair.
Noncompliance
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Figure 2: Interactions of  late complications of HSCT and  therapies.
-
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Table II - Classification of chronic GVHD
Limited
Signs or symptoms involving one organ system with at
least one biopsy showing characteristic pathological
findings of GVHD (may be in the same or in a different
organ system )
Either or both
− Localized skin involvement by histology
− Hepatic dysfunction due to chronic GVHD
Extensive
Signs or symptoms of cGVHD involving more than one
organ systems with at least one biopsy showing
characteristic pathological findings of GVHD
Either
− Generalized skin involvement by histology
− Localized skin involvement by histology and/or
hepatic dysfunction due to chronic GVHD
Plus
− Liver biopsy showing chronic aggressive hepatitis,
bridging necrosis or cirrhosis, or
− Involvement of eye (Schirmer’s test with less than
5 mm wetting),  or
− Involvement of minor salivary glands or oral mucosa
by labial biopsy,  or
− Involvement of any other target organ
NOTE: Patients with poor clinical performance (<60%
Karnofsky score) and at least one organ involvement are
classified as clinical extensive cGVHD .
edema and erythema of eyelids, decrease or premature
eyelashes are also manifestation of ocular cGVHD.
1.1.5. Vagina/Vulva
Vaginal dryness, dyspareunia, stricture
formation, stenosis, erythema, atrophy  and/or lichenoid
changes not secondary to ovarian failure are also
present in patients with cGVHD involving the vulvar
and vagina(12). Vagina or vulvar biopsy to confirm  the
diagnosis of cGVHD and cultures to rule out infection
are necessary. Follicular stimulant hormone and stradiol
levels are necessary to rule out gonadal failure as the
cause of the gynecological findings.
1.1.6. Liver
Abnormal liver function tests mainly show
cholestatic features. Other causes of elevated liver
function tests must be ruled out. Usually alkaline
phosphatase is >3x upper normal limits with/without
elevation of SGOT >4x upper normal values and/or
elevated total serum bilirubin >2.5 mg/dl. In the
absence of cGVHD involving other organs, liver biopsy
is required to confirm the diagnosis(13,14).
1.1.7. Lungs
Obstructive lung defect with forced expired
volume (FEV1)/forced vital capacity (FVC) <70% or
an FEV1 <80% of predicted or a decrease of FEV1/
FVC by >15% from previous pulmonary tests indicates
bronchiolitis obliterans. High resolution CAT scan
usually shows air trapping. Suspected bronchiolitis
obliterans requires negative microbiological tests in
bronchoalveolar lavage. Transbronchial biopsy is
required to confirm the diagnosis of bronchiolitis
obliterans in the absence of cGVHD involving other
organs(15-17).
1.1.8. Gastrointestinal System
Patients may develop dysphagia or odynophagia
with radiological evidence of esophageal stenosis  (on
barium swallow) or web formation on endoscopy and
occasional dysmotility(18,19). Anorexia, nausea,
vomiting, weight loss and diarrhea could be the
presenting symptoms. Endoscopic biopsy showing
characteristic pathological  findings are necessary to
confirm the diagnosis of cGVHD. Weight loss of more
than  15% body weight  not related to other causes  is
usually a sign of extensive chronic GVHD but it is not
always associated  with GI involvement . Malabsorption
syndrome is usually present in these patients(20).
1.1.3. Mouth
The development of new oral pain or dryness
after day 80 post-transplant should alert the physician
for the development of cGVHD because by that time,
chemo-radiotherapy-induced oral mucositis should have
resolved. Signs and symptoms of oral involvement by
cGVHD include dryness, burning, gingivitis, mucositis,
striae, atrophy, erythema, mucose atrophy, lichenoid
changes and ulcers. Atrophy, pigmentary and mottled
changes on the lip are also manifestation of cGVHD.
Tooth decay and tooth loss usually signs of ongoing
cGVHD. Lip biopsy shows characteristic pathological
findings(10).
1.1.4. Eyes
Ocular symptoms are the results of ocular sicca
and include: dryness, burning, blurring, gritty eyes,
photophobia and pain. Schirmer’s test shows a mean
value in both eyes of <5 mm at 5 minutes  or <10 mm
with signs of keratitis at slit light exam(11). Minimal
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1.1.9.  Musculoskeletal
Patients may have arthralgias involving the large
proximal girdle joints although  smaller joints may also
be affected. Contractures are usually secondary to
scleroderma or fasciitis. Proximal muscle weakness
with occasional cramping and elevation  of CPK and/
or aldolase can be seen. Electromyographic findings
are  consistent with myositis(21,22). Biopsy is needed to
confirm diagnosis if other organs are not involved.
Histological findings include necrotic fibers, interstitial
inflammation  and IgG deposits on immunoflurescence
staining. Myasthenia gravis  has been reported in few
cases(23).
1.1.10. Fasciae
Eosinophilic or sclerosing fasciitis characterized
by stiffness with restriction of movement due to in-
Table III - Performance scores and scales used to evaluate complications of HSCT
KARNOFSKY SCORE SYSTEM  (adults)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Normal; no symptoms or signs of active disease
Able to carry on normal activity; minor signs or symptoms of active disease
Normal activity with effort
Unable to do active work; cares for self
Requires occasional assistance
Requires considerable assistance and frequent medical care
Disabled; needs special care
Hospitalized; death not imminent
Hospitalized; critical condition
Moribund
Dead
LANSKY  PLAY-PERFORMANCE SCALE (children)
The Play-Performance Scale for children is designed to provide a standardized measure of the performance
status of the child with cancer and is appropriate for use with children aged 1 to 16.
Have parent select description which best describes child's play during the past week (average of good and
bad days)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Fully active, normal
Minor restrictions in physically strenuous activity
Active, but tires more quickly
Both greater restriction of and less time spent in play activity
Up and around, but minimal active play; keeps busy with quieter activities
Gets dressed but lies around much of the day, no active play, able to participate in all play
and activities
Mostly in bed; participates in quiet activities
In bed; needs assistance even for quiet play
Often sleeping; play entirely limited to very passive activities
No play; does not get out of bed
Unresponsive
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flammation and fibrosis involving the sheaths of ten-
dons can be seen in cGVHD(24). Occasionally, swell-
ing, erythema and pain may  affect the wrists, fore-
arms and hands, followed by ankles, legs and feet in a
decreasing order. Induration may be  present on pal-
pation and cramping is frequent. Patients are  unable
to extend the wrists without flexing the fingers or the
elbows.
1.1.11 Hematological Findings
Thrombocytopenia (usually >20.000/cu.mm) is
more often seen in  patients with progressive onset of
cGVHD. Thrombocytopenia  is a poor prognosis factor
if present at the time of diagnosis of  extensive
cGVHD(25-27). Eosinophilia is also present in some
patients with cGVHD.
Table IV - Classification of chronic GVHD according
to the type of onset of the disease
Progressive*
− Onset of cGVHD as a direct continuation of acute
GVHD
(i.e., persistent signs and symptoms of acute GVHD
at 3 months after HSCT)
Quiescent
− Onset of cGVHD after complete resolution of
acute GVHD manifestation (requiring <1.0 mg/kg of
steroids)
De novo**
− Onset of cGVHD with no prior history of acute
GVHD
*Worst prognosis.  **Best prognosis
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Figure 3: Sites involved by chronic graft-versus-host-disease (cGVHD) after either peripheral blood stem cell transplant
(PBSCT) or bone marrow transplant (BMT) in a prospective randomized phase III study, in patients transplanted in Seattle.
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1.1.12 Immunodeficiency
Recurrent infections, especially sinusitis, are
often manifestation of ongoing extensive cGVHD (28).
Hypogammaglobulinemia is usually present involving
IgG2 and IgG4 subclasses and IgA, including salivary
IgA. Occasionally hypergammaglobulinemia is present
and in few cases M-spike has been reported. Patients
with cGVHD with a history of recurrent sinusitis ben-
efit from surgical drainage and windows placement to
prevent subsequent and more serious infections.
1.2. Screening Studies for cGVHD
The median day of diagnosis of cGVHD in
HLA-identical sibling recipients is 201 days after
transplant; in contrast, HLA–non identical related and
unrelated donor marrow recipients have  earlier
diagnosis and onset of cGVHD. Fewer patients may
develop cGVHD after day +500. Screening test to
detect early cGVHD between 80-100 days after
allogeneic HSCT has been used for monitoring patients
in long-term follow-up(29). Screening studies for
cGVHD are summarized in Table V.
inflammation in eccrine coils and pilar units which leads
to fibrosis throughout the dermis. Liver biopsy reveals
bile duct damage similar to the histopathologic findings
of primary biliary cirrhosis(32).
1.4. Prevention of cGVHD
Although treatment with cyclosporine (CSP)
significantly reduces the incidence of acute GVHD,
the rate of cGVHD has remained unchanged in the
last two decades. No difference was observed in the
cumulative incidence of cGVHD in transplant
recipients receiving FK506/methotrexate (MTX)
prophylaxis compared to those given CSP/MTX
prophylaxis (reviewed in 7a). Results of a phase III
double-blind randomized trial with thalidomide for
prophylaxis of high-risk cGVHD were disappointing(66).
In another recent prospective randomized phase III
study for prophylaxis of extensive cGVHD in Seattle,
CSP given for 24 months after transplant did not reduce
the rate of cGVHD compared to patients receiving
CSP prophylaxis for 6 months.
1.5. Treatment of cGVHD
1.5.1 Primary Treatment
Initial attempts of treating cGVHD were largely
unsuccessful. In a prospective placebo-controlled study,
prednisone and azathioprine treatment improved
response and decreased disability of cGVHD
compared to prednisone alone(26). However, due to an
increased number of infectious complications in patients
treated with prednisone and azathioprine, survival was
as low as 47% compared to 61% in patients treated
with prednisone alone. This analysis included only
patients with platelet counts greater than 100.000/
cu.mm. Thirty-eight “high-risk” patients were placed
on prednisone alone.The non-relapse mortality for these
patients was 26% and the survival rate was 58%(26).
Oral CSP in patients with cGVHD with
thrombocytopenia was also studied(31). Renal toxicity
was modest and survival improved while infections
decreased with this clinical trial. Average duration of
therapy was 1 to 2 years. Again, in these high risk
group of patients, infection remained a frequent cause
of morbidity and contributed to transplant-related
mortality in patients with high-risk cGVHD(31).
In a prospective randomized study, alternating
day CSP and prednisone therapy for high-risk cGVHD
(platelets less than 100.000/cu.mm) appeared to
produce a higher response rate compared to CSP
Table V - Screening tests for chronic GVHD
− Skin and oral examination
− Skin biopsy
− Lip biopsy (if clinically indicated)
− Schirmer’s tear test and slit lamp examination of
eyes
− Liver function tests
− Pulmonary function tests
− Gynecological evaluation
− Weight, muscle/fat store measurement
− Karnofsky score or Lansky play index (Table III)
1.3. Diagnosis of cGVHD
Concomitant pathologies including infections and
drug reactions need to be ruled out in patients
suspected to have manifestations of cGVHD.
Histological documentation of cGVHD by skin or other
tissue biopsy is necessary for diagnosis(2,30). Pathologic
findings in the skin include localized epidermal atrophy
and dense focal dermal fibrosis in the absence of
significant inflammation. In other patients, more
generalized histological manifestations are seen  with
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alone(31-33). However, the 3-year actuarial survival for
this group of patients remained low at 48% and the
non-relapse mortality rate was 35% with the
combination therapy(32). The survival and the non-
relapse mortality rates were not significantly different
between the two arms of the study (CSP/PRED versus
CSP). The 3-year survival was 48% in patients who
received primary therapy and infections appeared to
be reduced in the long-term survivors(32).
In another a prospective, randomized placebo-
control trial, comparing thalidomide or placebo in
combination with PRED/CSP (or FK-506) for
treatment of high risk cGVHD (i.e., progressive onset
or platelets less than 100.000/cu.mm) the 3-year
survival was similar at approximately 50% in the two
arms of the study. Thalidomide intolerance was high
in this study leading to premature discontinuation of
the drug in the majority of the patients. There was a
suggestion that thalidomide in combination with PDN/
CSA (or FK-506) might induce more tolerance (64).
1.5.2 Secondary Treatment
Corticosteroid dependent or resistant cGVHD
is extremely difficult to manage and is associated
with high morbidity and mortality. Criteria of response
to therapy and definition of failure are summarized
below (Section 1.5.4., Table VII). Numerous small
series and case reports describing the results of
different therapies in cGVHD have been reported or
are under investigation including azathioprine,
alternating-day steroids with CSA or FK-506
(tacrolimus, Prograf), psoralem and ultraviolet light
(PUVA), thalidomide, clofazimine, retinoic acid
derivatives, ursodeoxycholic acid, mycophelolic mofetil
(MMF), rapamycin, monoclonal antibodies and, more
recently, extracorporeal photoimmunotherapy (ECP)
and receptor antagonist agents against tumor necrosis
factor-alpha (Table VI) (32-42,63).
Azathioprine, alternating CSP/prednisone and
thalidomide given as secondary therapy in patients with
Table VI - Medications used in chronic graft-versus-host disease
DoseGeneric Name Brand name
in USA Oral I.V.
Major Side Effects
Cyclosporine Sandimmune
Neoral
6.25 mg/kg BID
5.0 mg/kg BID
1.5 mg /kg BID
Not available
Nephrotoxicity (creatinine & BUN
elevation), hypomagnesemia,
hepatotoxicity (rise in bilirubin,
ALT/AST); neurotoxicity (tremor,
paresthesias, headache, seizures),
hirsutism, hemolytic uremic syndrome,
hypertension, hyperglycemia, gum
hyperthrophy, anxiety, depression,
fatigue.
Tacrolimus
(FK-506)
Prograf 0.15-0.30
mg/kg/day BID
0.05-0.10
mg/kg/day
(continuous
infusion)
Nephrotoxicity (creatinine & BUN
elevation), hepatotoxicity (rise in
ALT/AST and in bilirubin); neurotoxicity
(seizures, agitation neuropathy,
paresthesias), headache, nausea,
vomiting, skin rash, hyperkalemia,
hyperglycemia.
Mycophenolate
Mofetil (MMF)
Cell Cept 1 gm BID Not available Vomiting, diarrhea, neutropenia,
anemia.
Rapamycin Rapamune
Sirolimus
2 mg/day Not available Neutropenia, thrombocytopenia, rise in
cholesterol &  triglycerides.
Thalidomide Thalidomid 200 - 400 mg/day Not available Birth defects, sedation, constipation,
neutropenia, peripheral neuropathy,
weakness, dysesthesias, clumsiness,
sleepiness
BUN: bound urea nitrogen, AST: aspartate transaminase, ALT: alanine transaminase
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cGVHD have resulted in similar survival rates (34-35).
A larger thalidomide clinical trial for salvage therapy
of cGVHD has been reported (34).  Response has been
observed in 20% of patients treated with
thalidomide(35,36).  Use of PUVA (psoralen plus UV
light) has been shown to be beneficial in patients with
refractory cutaneous cGVHD(40-42). In patients with
isolated skin involvement without scleroderma  PUVA
may be considered as the first line therapy. Some
patients with morphea have been reported to benefit
from PUVA alone.  Randomized prospective trials with
PUVA for cGVHD have not been reported.
In spite of several numbers of therapies reported
as phase I-II studies, little advances have been made
in the last decade for patients with high-risk
cGVHD(32,37-39). Challenges in clinical trials of cGVHD
include the poorly understood pathophysiology of the
disease, absence of a validated staging system,
difficulty in measuring changes, indirect management
of patient care, insurance coverage, and low enrollment
in phase III clinical trials. Collaborative efforts are
under way to validate a new staging system for
assessing cGVHD response and outcome.
1.5.3 Supportive Care
Supportive or adjuvant therapy of cGVHD:
Topical steroids can be successful for treatment of
oral, vaginal/vulvar, or penile lesions secondary to
cGVHD. Patients with ocular sicca may respond to
retinoic acid and oral sicca may respond to pilocarpine.
In addition to artificial tears, patients with severe ocu-
lar sicca requires ligation of lacrimal puncti. Muscular
cramps and carpal spasm may be relieved by
clonazepam, klonipin or beclofen. In patients with liver
function abnormalities and refractory hepatic chronic
GVHD, bile acid replacement therapy with
ursodeoxycholic acid (UDCA or Ursodiol) has been
shown to be beneficial.
Osteoporosis or osteopenia prevention: To
decrease some of the toxicity of long-term corticos-
teroids treatment, patients are recommended to re-
ceive estrogen replacement (women), meet the daily
requirements of calcium (1500 mg/d in diet or supple-
ment) and daily vitamin-D requirments(800 IU/d in diet
or supplement), weight bearing exercise; bisphos-
fonates should be considered or studied. A baseline
and annually bone density studies to assess bone mass
loss are also important(55).
Gonadal failure: Pre-menopausal females
prior to transplantation should receive gonadal replace-
ment therapy following transplant. Women who de-
cline estrogen therapy or for whom replacement is
inappropriate (patients with a history or high risk of
breast cancer), should be treated with calcitonin. Males
with low free testosterone levels should receive test-
osterone replacement. Baseline prostate examination,
PSA, lipid profile and liver function tests should be
monitored in patients treated with testosterone.
1.5.4  Definition of Response
No response or progression (failure):
Deterioration of cGVHD in at least one organ after 9-
12 months of therapy without improvement in other
organs. This category also includes patients with stable
cGVHD but who have persisting Karnofsky or Lansky
scores less than 50 %.
Partial response: After 9-12 months of
therapy cGVHD is clinically stable or improved in at
least one evaluable organ without deterioration in
others. If there is still a partial response after 18 to 24
months, cGVHD is considered to have failed
treatment. Patients with improvement of skin and
other organs involved by cGVHD, but persistent oral
involvement, are considered partial responders.
Complete Response: After 9-12 months of
therapy the patient is well and has resolution of all
symptoms and signs of active cGVHD. Patients with
complete response in all organs, but with persistent
ocular sicca, will be considered complete responders.
Clinical responders should be divided into two
categories: (A) clinical and histologically complete
responses, and (B) complete clinical response but
persistent histological involvement.
Exacerbation/flare: When treatment is reduced
or stopped after achieving a complete or partial response,
patients develop exacerbation of cGVHD manifestation
requiring systemic immunosuppressive therapy.
Patients needs to be followed by their primary
physician at monthly intervals. Physical examinations,
weight, liver function tests, complete blood cell counts,
renal function tests, and drug leves should be care-
fully monitored.
1.5.5 Measurement of Response
Involvement of the skin (surface area, hair  and
nails), oral cavity, eyes (Schirmer’s test), liver (serum
bilirubin and alkaline phosphatase), gut (weight loss,
malabsorption, volume of diarrhea, cramps or bleeding),
musculoskeletal (range of motion, CPK, aldolase) is
evaluated.
Table VII summarizes the criteria used to assess
treatment response in patients with cGVHD.
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1.5.5.1 Skin
To evaluate treatment response in cutaneous
cGVHD, a “Grid” approach should be used (Figure
4), complemented by comparative photographs and by
the modified Rodnam skin score when scleroderma is
present (Table VIII). Skin is considered to be improved
if there is a 25% decrease of the surface areas involved
by rash, sclerosis, lichenoid or dyspigmentation;
regrowth of hair in previous sclerotic areas; softening
of the skin in >25% of previous involved areas, or
increased range of motions by > 25% in one or more
joints without deteriorations in others.
1.5.5.2 Liver
Liver disease is considered improved if  there
is a) a decrease in serum bilirubin to less than 2 mg/dl
for patients with baseline values of 2 to 4 mg/dl, or b)
a decrease of  >2 mg%/dl for patients with baseline
values of 4 to 8 mg/dl, or c) >25% decrease in serum
bilirubin for patients with baseline values >8 mg/dl, or
d) if alkaline phosphatase decreases to < 200 mg/dl
for patients with baseline values of 250 to 300 mg/dl,
or e) >25% decrease in alkaline phosphatase for
patients with baseline values >300 mg/dl.
1.5.5.3 Gastro-intestinal tract (GI)
GI disease is considered improved if there is a
cessation of weight loss or weight gain (i.e. >1 Kg in a
Table VII - Evaluation of response to tratment in cGVHD
DEFINITION OF RESPONSE (after 9-12 months of therapy):
No response or failure: deterioration in at least one evaluable organ w/o improvement in others or stable organ
involvement w/ persisting performance score <50% or partial response after 18-24 months of treatment
Partial response: stabilization or improvement in at least one evaluable organ w/o deterioration in others or
improvement of skin or other organs w/ active oral involvement
Complete response: resolution of all symptoms and signs of active cGVHD w/ or w/o persistent ocular sicca
syndrome. Histological involvement may persist in spite of clinical response
Exacerbation: manifestation of cGVHD returns after stopping or reducing treatment.
MEASUREMENT OF RESPONSE IN DIFFERENT ORGANS:
Skin: use the “Grid” approach (Fig. 4),  comparative photographs or the Rodnan skin score for escleroderma
(Table VIII). Improvement is  a) decrease by > 25% of involved areas, b) increase in range of motion by >25%  in
one or more joints w/o deterioration in others.
Liver: Improvement defined by decrease in serum bilirrubin or in alkaline phosphatase by  >25%
Gastrointestinal tract: a) cessation of weight loss or weight gain, b) resolution of diarrhea or decrease by >500 ml
in the 3 day average stool volume, c) resolution of  cramps and bleeding
3 month interval), or resolution of diarrhea, or a
decrease in the three day average stool volume by
>500 ml with clearing of cramps and bleeding, if
present.
2. REGIMEN-RELATED TOXICITIES
Late complications after allogeneic and
autologous hematopoietic stem cell transplantation may
arise from chemotherapy and/or radiotherapy
associated organ toxicity(2). These potential late effects
of myeloablative conditioning regimens include
cataracts, neurological problems, gonadal failure,
endocrine problems, growth and development
impairments (Table I, Figs. 1 and 2). These regimen -
related complications are briefly reviewed below.
2.1. Cataracts
Cataract formation after transplant is due to
corticosteroid and total body irradiation (TBI). In the
analysis of 492 adults followed for a median of 6 years
after bone marrow transplantation, cataracts developed
in 159 patients (32%). The probability of cataract
formation at 11 years after transplantation was 85%
for patients receiving 10 Gy single dose TBI, 50% for
patients receiving more than 12 Gy and 19% for patients
who were not conditioned with TBI(43). Steroids
administered  after Day +100 also appeared to increase
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Figure 4: The “GRID” approach to assess cutaneous involvement in cGVHD. Each involved area is shaded by the examiner
and the nature of the lesion (scleroderma, lichen, dyspigmentation, papules, ulcers, rash or other) is identified.
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the risk of  cataracts seen after TBI. Patients who
were treated with steroids  post-transplantation had a
significantly higher probability of cataracts (45%) than
those who did not receive steroids (38%).
2.2. Neurological Complications
Late neurological complications may result from
previous cranial radiation, recurrence of the primary
disease, drug toxicities (CSP, FK-506, etc) and
infections (HHV-6, HSV, VZV, fungal, bacterial and
protozoa). Leukoencephalopathy may develop in
patients who receive intrathecal methotrexate or other
chemotherapic agents and cranial irradiation and the
risk may increase in young patients who receive more
than six doses of intrathecal methotrexate after the
transplant(44). Late neurologic abnormalities may also
be seen in patients receiving nitrogen mustard as part
of the preparative conditioning regimen.
2.3.  Endocrine and Growth Abnormalities
Myeloablative conditioning regimens may also
affect the endocrine system, growth and development.
In adult bone marrow transplant patients, two thirds
of the recipients may have elevated TSH with normal
blood T4 and T3 levels(45). In the same study,  it was
also shown that 20 % to 25% of the patients will develop
definite hypothroidism. Thyroid deficiency was
reported in 31% to 43% of patients after single fraction
of TBI. Thyroid hormone replacement should be
administered if the diagnosis of hypothyroidism has
been confirmed. In view of the clinical studies
mentioned, thyroid function studies must be done
annually in all  bone marrow transplant recipients.
Growth hormone deficiency has also been reported
following TBI(46). It may be higher than 90% in the
pediatric patients conditioned with TBI  who also had
a history of cranial irradiation for CNS leukemia (46).
In some children who were treated with corticosteroids
for chronic graft-versus-host disease (cGVHD),
growth rate may be lower compared to the period
during which steroids are discontinued. Concurrent
drug therapies such as prednisone may cause
emotional  problems, rarely psychosis, and cyclosporine
may cause tremors, seizures, muscle cramps and
lethargy.
2.4. Gonadal Dysfunction
Gonadal function abnormalities are quite
frequently observed as a result of myeloablative
chemotherapy and radiotherapy. Gonadal dysfunction
has been closely associated with alkylating agents, may
be related to patient’s age and the intensity of the
chemotherapy regimen. Female patients may have
anovulation, low estrogen levels and elevation of serum
gonadotropins(47). Patients who were conditioned with
TBI containing preparative regimens rarely have return
of their fertility(47,48).
Hormone replacement with cyclic estrogen/
progesterone therapy is employed to prevent
osteoporosis and its complications of early menopause.
Most women prefer Premarin 0.625 mg to 1.25 mg
per day (P.O) and Provera 2.5 to 5.0 mg on days 1-14
of the menstrual cycle (P.O.). Both of these medica-
tions are well-tolerated. Provera is not indicated in
women who had hysterectomy.
2.5. Gynecologic and Obstetric Complications
Post-pubertal female patients who received TBI
containing regimes have been shown to have climac-
teric abnormalities(48). Appropriate and early hormone
Table VIII - Modified Rodnan Skin Score for
Assessment of Sclerodermic Involvement
The modified Rodnan skin score is calculated by
summing the scores from all evaluated anatomic areas
A. Evaluation of skin thickness rated by clinical
palpation
0= Normal, 1= Mild, 2= Moderate,
3= Severe (Inability to pinch skin into a fold)
B. Surface of anatomic areas evaluated (N= 17)
Face
Anterior chest
Abdomen
Fingers
Dorsum of hands
Forearms
Upper arms
Thighs
Lower legs
Dorsum of feet
Right
Left
Right
Left
Right
Left
Right
Left
Right
Left
Right
Left
Right
Left
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
0-3
TOTAL 0-51
Ref: J. Rheumatol 1993, 20 (11): 1892-1896.
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replacement with estrogen and progestrone may re-
duce the risk of osteoporosis and eliminate unneces-
sary discomfort. Although pre-term delivery and low-
birth weight children were reported to be higher than
expected in the bone marrow recipients, the incidence
of congenital abnormalities did not appear to be differ-
ent than the rates observed in the general population.
3. IMMUNODEFICIENCY AND INFECTIONS
Both allogeneic and autologous hematopoietic
stem cell recipients experience impaired immunological
changes for 6 to 12 months post-transplant (49). HLA-
disparity of the allogeneic donor and presence of
chronic GVHD is associated with both cellular and
humoral immunodeficiency(50). Levels of CD4+ T-
helper lymphocytes may stay low  within the first six
months after transplantation while normal numbers of
peripheral blood  B-cells can be found one to two
months after BMT. In general, the patients are
expected to reach normal levels of serum IgG within
2-3 months posttransplantation, of serum IgM in 9-12
months and  of IgA  in 2 to 3 years. Normalization of
the serum immunoglobulin levels is delayed in patients
with chronic GVHD. For the first year after
transplantation patients with hypogammaglobulinemia
(serum IgG levels less than 400 mg/dl) should receive
I.V. immunoglobulin therapy to reduce the risk of
infections(51, 52).
All marrow transplant recipients undergo a state
of immune deficiency which is most severe in the first
6-12 months post-transplant. It is during this time that
most bacterial, fungal and viral infections occur. After
12 months post-transplant most patients will achieve
adequate immune reconstitution unless they develop
cGVHD.
3.1. Antimicrobial Prophylaxis
Pneumocystis carinii (PCP) prophilaxis is rec-
ommended until six months posttransplant or until all
immunosuppressive therapy is discontinued. Patients
not able to receive trimethoprim-sulfamethoxazole
should receive PCP prophylaxis with dapsone (50-100
mg PO daily). Patients receiving treatment for
cGVHD need to receive prophylaxis against encapsu-
lated bacterial infections such as H.influenzae and S.
pneumoniae. Daily trimethoprim-sulfamethoxazole
(double-strength, one tablet PO daily) are an adequate
regimen for prophylaxis of both PCP and encapsu-
lated bacterial infections. If twice-weekly trimethoprim-
sulfamethoxazole is choosed for PCP prophylaxis,
Penicillin-V (500 mg TID) must be added for encap-
sulated infection prophylaxis in patients receiving sys-
temic immunosuppressive treatment for cGVHD.
3.2.  Immunizations
After the first year post-transplant booster
vaccination is recommended for optimal antibody
response. Booster immunization is recommended
against pneumococcus, hemophilus, hepatitis B,
diphteria, pertussis (only for patients <7 years old),
tetanus  and inactivated polio. Whether patients with
cGVHD will develop an antibody response is not
known in all cases. Antibody titers can be helpful if
drawn before vaccinations. If pre-immunization titers
are low or unknown, repeat vaccinations up to 2 times
in 2 month intervals, except for Pneumococcus.
Influenza vaccination is recommended (yearly).
Should the oral polio vaccine (OPV) be given
to family infants or others in close contact with the
patient within the first year after transplantation or
while on immunosuppressive therapy, the patient should
be isolated from the person vaccinated for 8 to 12
weeks which is the period of potential live virus
shedding. Immunization schedule post-HSCT is
summarized in Table IX.
Antibody titers should be tested before the first
vaccination and may also be tested 4 weeks afterwards
to help evaluate the antibody response.  Patients with
unknown pre-vaccination antibody titers should com-
plete the entire series of vaccinations listed above,
unless contraindicated.  The 2nd and the 3rd doses of
DPT, HiB and Salk poliovirus are recommended for
patients who have nonprotective antibody titers.
Patients who continue to have nonprotective titers after
administration of Pneumovax at one year after
transplantation should receive a second dose at two
years, unless there is a history of severe local reaction
or other contraindication.
4. BONE DISEASE
Bone loss is a well-recognized complication of
glucocorticoid therapy in doses as low as 7.5 mg daily.
In hematopoietic stem cell transplant patients, other
factors such as electrolyte imbalances, inactivity, sig-
nificant weight loss and endocrine deficiencies may
also contribute to bone loss. Management for preven-
tion of bone loss includes minimizing glucocorticoid
dose, optimizing calcium and vitamin-D intake, stimu-
lating weight-bearing exercise and providing hormone
replacement therapy for gonadal failure(53-55).
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4.1. Avascular Necrosis (AVN)
Approximately 10% of all allogeneic bone
marrow transplant recipients may develop AVN and
its incidence is more than 3 folds in patients with chronic
GVHD, with an odds ratio of 19.1 in patients on
steroids. Five year estimated cumulative incidence of
osteonecrosis is 4 to 11 % depending upon risk factors.
Patients without history of cGVHD have the lowest
risk of AVN compared to those with extensive
cGVHD. For these reasons, currently, patients having
hip or bone pains should be evaluated with MRI of the
hips and knees or other joints as clinically indicated.
Approximately 40% of patients will require hip
replacement between 2 to 42 months after diagnosis.
Core decompression of the femoral head can benefit
some patients with early osteonecrosis.
Table IX - Recommended vaccinations after hematopoietic cell transplantation
Time After Transplant Vaccines
≥ 1 year¶ Diphtheria-Pertussis*-Tetanus (DPT)
Haemophilus influenzae type B (HiB)
Hepatitis B
Salk poliovirus (inactivated vaccine)
Pneumococcal vaccine (Pneumovax)
Influenza (every fall /winter)
Hepatitis A (only patients at risk) †
1 - 2 months after initial dose¶ Diphtheria-Pertussis*-Tetanus (DPT)
Haemophilus influenzae type B (HiB)
Hepatitis B
Salk poliovirus (inactivated vaccine)
Hepatitis A (only patients at risk)†
4 - 6 months after initial dose¶ Diphtheria-Pertussis*-Tetanus (DPT)
Haemophilus influenzae type B (HiB)
Hepatitis BSalk poliovirus (inactivated vaccine)
> 2 years after transplant and > 1 year without
immunosuppressive therapy
Measles, Mumps, Rubella (MMR)‡
Varicella-Zoster Virus (VZV)‡
¶
 Antibody titers should be tested before the first vaccination and may also be tested 4 weeks afterwards to help
evaluate the antibody response.  Patients with unknown pre-vaccination antibody titers should complete the entire
series of vaccinations listed above, unless contraindicated.  The 2nd and the 3rd doses of DPT, HiB and Salk poliovirus
are recommended for patients who have nonprotective antibody titers.  Patients who continue to have nonprotective
titers after administration of Pneumovax at one year after transplantation should receive a second dose at two years,
unless there is a history of severe local reaction or other contraindication.
*  Pertussis vaccine should be administered only to children less than 7 years of age.
† 
  Hepatitis A vaccine should be given only to patients with a history of hepatitis B or C, liver GVHD, other chronic liver
disease, or increased risk because of travel or residence in an underdeveloped region.
‡
  MMR and attenuated VZV vaccines should not be given until 2 years after the transplant or at least 1 year after
discontinuation of all treatment with IV Ig and immunosuppressive medications, whichever occurs later. Varicella
vaccine may be given only to VZV-seronegative patients. Vaccination should be deferred until at least 5 months after
the administration of IV Ig or VZ Ig or the most recent blood or plasma transfusion.  No IV Ig should be given for at
least 2 months after vaccination, unless the need outweighs the benefit of vaccination. Varicella vaccine can be given
concurrently with MMR vaccine. The second dose of Varicella-Zoster vaccine should be administered 1 month after
the first dose. Other live virus vaccines (oral polio, yellow fever and smallpox) may carry risk in immunocompromised
patients and should be avoided.
5. RELAPSE OF  MALIGNANCY
The risk of relapse following transplant for he-
matologic malignancies is greatest in patients trans-
planted during relapse. Most recurrences occur within
1-2 years posttransplant and few relapses have been
seen after three years. If the hematologic counts or
peripheral smear examination change, the marrow
exam and cytogenetics should be repeated.  In Se-
attle, we  routinely perform a marrow aspirate around
day 80 posttransplant, but we do not recommend rou-
tine marrow exams again until the one-year visit to
the clinic. For all patients with CML Ph1+ or ALL
Ph1+ we recommend blood and marrow collections
for cytogenetic and molecular studies every 6 months
for 2 years after transplant and then annually(56).  Al-
though some patients may be placed into a subsequent
429
Long term complications of HSCT
remission with chemotherapy reinduction, its duration
is usually short. Other approaches would include bio-
logic response modifiers(57), donor lymphocyte (DLI)
infusions(58,59) or a second transplant.
6. SECONDARY MALIGNANCIES
Malignant tumors following TBI have been ob-
served in several animal studies.  In human recipients of
marrow transplants followed since 1970, non-Hodgkin’s
lymphomas, leukemias and solid tumors have been
identified in a small proportion of patients (35 of  2,246
transplants, 1.5 %).  The risk of developing a second-
ary malignancy is highest in the first year after trans-
plant at which time it is 1.2 events/100 patient-years
of exposure.  The risk falls in the second year after
transplant to 0.4 events/100 patient-years and remains
at that level thereafter. These statistics are based on
the observation of our patient population for the past
17 years(60,61). In a multi-institutional data base, 19,229
recipients of allogeneic marrow transplants were ana-
lyzed to determine the risk of developing late solid can-
cers(62). The risk of new solid cancers was 8.3 times
higher than expected for the general population among
those who survived 10 or more years after transplan-
tation(62). In this study, the risk of developing new solid
cancers was also found to be higher for recipients who
were younger  at the time of transplantation.
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